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Abstract
Background Gastric cancer, a leading cause of cancer
death worldwide, has been little studied compared with
other cancers that impose similar health burdens. Our goal
is to assess genomic copy-number loss and the possible
functional consequences and therapeutic implications
thereof across a large series of gastric adenocarcinomas.
Methods We used high-density single-nucleotide poly-
morphism microarrays to determine patterns of copy-
number loss and allelic imbalance in 74 gastric adenocar-
cinomas. We investigated whether suppressor of tumori-
genesis and/or proliferation (STOP) genes are associated
with genomic copy-number loss. We also analyzed the
extent to which copy-number loss affects Copy-number
alterations Yielding Cancer Liabilities Owing to Partial
losS (CYCLOPS) genes–genes that may be attractive tar-
gets for therapeutic inhibition when partially deleted.
Results The proportion of the genome subject to copy-
number loss varies considerably from tumor to tumor, with
a median of 5.5 %, and a mean of 12 % (range 0–58.5 %).
On average, 91 STOP genes were subject to copy-number
loss per tumor (median 35, range 0–452), and STOP genes
tended to have lower copy-number compared with the rest
of the genes. Furthermore, on average, 1.6 CYCLOPS
genes per tumor were both subject to copy-number loss and
downregulated, and 51.4 % of the tumors had at least one
such gene.
Conclusions The enrichment of STOP genes in regions of
copy-number loss indicates that their deletion may con-
tribute to gastric carcinogenesis. Furthermore, the presence
of several deleted and downregulated CYCLOPS genes in
some tumors suggests potential therapeutic targets in these
tumors.
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Introduction
Gastric cancer is the fourth commonest cancer in the world
and a leading cause of cancer death [1]. In 2008, it caused
738,000 deaths (10 % of all cancer-related deaths) [2].
Gastric cancer is especially prevalent in East Asia, Eastern
Europe, and parts of Central America and South America
[2]. Current treatments offer only slight survival benefits.
Except in Japan, where endoscopic screening often detects
early-stage tumors, the overall 5-year survival rate is
20–25 % [3].
Although there have been many studies of loss of
heterozygosity (LOH) and copy-number loss in gastric
cancer [4–9], to our knowledge none of these studies sys-
tematically surveyed copy-number loss and its effects on
genes retarding proliferation or genes that, when deleted,
might constitute therapeutic vulnerabilities. At present,
high-density microarrays provide simultaneous assessment
of single-nucleotide polymorphism (SNP) genotype and
genomic copy number at hundreds of thousands of sites
across the genome, and can thus delineate regions of copy-
number loss [10].
It has recently emerged that copy-number loss is likely
important in two distinct aspects of cancer biology. In one
aspect, it appears that copy-number loss can promote
proliferation by reducing expression of genes that would
otherwise inhibit it; these have been termed ‘‘suppressor of
tumorigenesis and/or proliferation genes’’ (STOP genes)
[11]. These genes were previously identified in short-
hairpin RNA screens for genes that tend to inhibit prolif-
eration. In subsequent statistical analysis across more than
25 cancer types, these genes were found to be enriched in
regions of recurrent deletion as determined by the Genomic
Identification of Significant Targets In Cancer (GISTIC)
method [12, 13].
In the second aspect, it is likely that copy-number loss
often affects innocent bystander genes; the copy-number
loss of these genes per se might not promote oncogenesis
but instead incidentally makes cells more vulnerable to
drugs targeting these genes. The model is that some of
these genes already have reduced expression due to copy-
number loss, and, as a consequence, would be more sus-
ceptible to inhibition by drugs. Such genes have been
dubbed ‘‘Copy-number alterations Yielding Cancer Lia-
bilities Owing to Partial losS genes’’ (CYCLOPS genes)
[14]. These are conceptually distinct from STOP genes.
The deletion of STOP genes confers a selective advantage
to cancer cells, but, by contrast, the deletion of CYCLOPS
genes is merely incidental, even though it presents a
therapeutic opportunity. Nijhawan et al. [14] recently
generated a list of probable CYCLOPS genes by associ-
ating information on cancer cell lines’ dependency on
genes with information on copy-number loss of the genes
in these cell lines. As determined in that previous study, a
likely CYCLOPS gene was one with the property that cell
lines that had copy-number loss at that gene also tended to
be sensitive to the gene’s knockdown.
The criteria for CYCLOPS genes are more stringent
than those for STOP genes, and this is reflected in their
numbers: 55 CYCLOPS genes [14] compared with 878
STOP genes [11]. The list of CYCLOPS genes was gen-
erated on the basis of an observed association of copy-
number loss with sensitivity to knockdown. By contrast,
the list of STOP genes was based solely on the observation
of reduced proliferation in cells in which the genes were
knocked down, although subsequent analysis of STOP
genes showed an aggregate statistical association with
copy-number loss.
It is unknown to what extent copy-number loss of STOP
genes plays a role in gastric adenocarcinoma and to what
extent gastric adenocarcinomas harbor deletions of
CYCLOPS genes. To investigate these questions, in the
present study we used assays of approximately 906,600
SNPs in 74 tumors and matched nonmalignant tissue to
delineate high-resolution, comprehensive views of copy-
number loss and LOH in gastric adenocarcinomas. We then
investigated the effects of copy-number loss on STOP and
CYCLOPS genes in these tumors.
Materials and methods
Patients and samples
Primary gastric adenocarcinomas and matched nonmalig-
nant tissue samples were obtained from Singapore Health
Services with approval from the institutional review board.
All samples were obtained with signed informed consent.
Table S1 summarizes tumor and patient characteristics. For
some of the tumors, the pathologist-estimated tumor con-
tent was very low, in some cases zero. We nevertheless
analyzed these tumors because our experience has shown
that pathologists, working with a portion of the surgically
resected material different from that of the frozen sample
from which DNA was extracted, often produce estimates of
tumor content very different from those detected in DNA
from the frozen portions of the tumor. Furthermore, tumors
with very low tumor content can later be excluded from
analysis because they have flat B-allele frequencies (BAFs)
across the entire genome, as discussed in detail in ‘‘Re-
sults’’ and in ‘‘ASCAT profiling of allele-specific copy
numbers.’’
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DNA extraction and hybridization
Genomic DNA from snap-frozen gastric tumors and adja-
cent nonmalignant gastric tissues was extracted with a
Qiagen genomic DNA extraction kit. The DNA was then
hybridized to Affymetrix Human Mapping SNP 6.0 arrays
(Affymetrix, Santa Clara, CA, USA) according to the
manufacturer’s protocol. The chips were scanned with a
GeneChip scanner using the Affymetrix GeneChip Oper-
ating Software. SNP positions were represented according
to the hg18 (build 36) version of the human genome ref-
erence sequence. Some of the array data were previously
published in [15]. All the array data used in this work have
been deposited in Gene Expression Omnibus (accession
numbers GSE31168 and GSE67965).
SNP array data preprocessing
We used Copy-number estimation using Robust Multichip
Analysis version 2 (CRMA v2) [16] to extract intensity
values for both alleles of each SNP from the SNP array data
in the CEL files. In this process, CRMA attempts to account
for (1) cross talk between alleles, (2) probe-sequence effects,
and (3) the effects of the various sizes of fragments gener-
ated by restriction enzyme digestion before hybridization.
We then processed each tumor and nonmalignant pair with
TumorBoost [17] to increase the signal-to-noise ratio of
allele-specific signals. This improved the ability of subse-
quent analysis to detect copy-number loss, LOH, and allelic
imbalance. Matched nonmalignant samples were used as the
reference to generate log2 R ratios (LRRs) and BAFs for the
SNPs. The LRR of a SNP is the log2 of the signal intensity at
that SNP (summed over both alleles) in the tumor sample
divided by the signal intensity in the matched nonmalignant
sample. The BAF of a SNP is the proportion of the total
signal in the tumor that derives from the nonreference allele
[the nonreference allele is designated the B allele, whence
the term ‘‘B-allele frequency’’ (BAF)].
ASCAT profiling of allele-specific copy numbers
We used Allele-Specific Copy number Analysis of Tumors
(ASCAT) program [10] to estimate allele-specific copy
numbers from the LRRs and BAFs while accounting for the
effects of cancer-cell polyploidy and aneuploidy and the
effects of the admixture of DNA from nonmalignant cells
(Fig. 1). We selected ASCAT after we had evaluated several
other analytical software packages, including Copy Number
Analyzer for GeneChip (CNAG) [18] and Genome Alter-
ation Print (GAP) [19]. For evaluation we used published
data from a dilution series of cancer cell line DNA mixed
with DNA from nonmalignant tissue from the same person
[20]. We evaluated the software packages on the basis of
their ability (1) to detect LOH and allelic copy numbers in
tumors with a low proportion of malignant cells and (2) to be
used in semiautomated fashion from the command line.
Details of the evaluation are presented in [21]. We also
analyzed the tumors with GAP and Global Parameter Hidden
Markov Model (GPHMM) [22]. We found that GAP was
often unable to detect allelic imbalance from the BAF data
(Fig. S1). We believe this is because GAP is not able to use
TumorBoost-processed data. GPHMM was able to use
TumorBoost-processed data, but often created an implausi-
bly large number of segments (Fig. S2). In summary, we
believe that ASCAT provides the most reliable estimates of
copy number, allelic imbalance, and proportion of malignant
cells in the tumor DNA sample.
ASCAT was not originally designed for Affymetrix SNP
array technology [10], and we made several minor modi-
fications to it to allow it to work more effectively with
Affymetrix Human Mapping SNP 6.0 arrays; patch files for
modifying the original ASCAT program are available on
request.
The main inputs to ASCAT are LRRs and BAFs com-
puted from a tumor and matched nonmalignant tissue as
described above (Fig. 1, panels a, b). ASCAT analyzes the
LRRs and BAFs for those SNPs that are heterozygous in
the nonmalignant sample. These are the SNPs that are
informative with respect to allelic imbalance. ASCAT
segments the LRRs and BAFs to smooth random SNP-to-
SNP variation. The green dots in Fig. 1a and b show the
segmented LRRs and BAFs, superimposed on the original,
unsegmented values, which are indicated by the red dots.
After segmentation, ASCAT generates genome-wide
allele-specific copy-number profiles (Fig. 1, panels d, e).
The profiles (1) estimate the proportion of malignant and
nonmalignant cells in the tumor sample (‘‘aberrant cell
fraction’’ in Fig. 1e), (2) estimate allele-specific copy
numbers of chromosomal segments across the genome
(Fig. 1d, red and green horizontal lines), and (3) provide
reliability measures for these estimates (Fig. 1e). ASCAT
also provides an average ploidy for the cancer cells in the
tumor samples; this is the average of the copy numbers of
informative SNPs across the genome (‘‘ploidy’’ in Fig. 1d).
List of tumor suppressor genes
We identified the tumor suppressor genes (TSGs) in
Table 1 from two sources. The first was the Sanger Cancer
Gene Census, an actively maintained, curated list of can-
cer-related genes, first described in [23], downloaded from
http://cancer.sanger.ac.uk/cancergenome/assets/cancer_gene
_census.tsv on May 24, 2013. The second source was the
supplementary information in [24], worksheets Table S2A
and Table S2B in the file http://www.sciencemag.org/
content/suppl/2013/03/27/339.6127.1546.DC1/1235122
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TablesS1-4.xlsx. We treated a gene as a TSG if it was listed
as ‘‘rec’’ (recessive) in the Cancer Gene Census or listed as
‘‘TSG’’ in [24].
Analysis of STOP genes
STOP genes are suppressors of proliferation that were
identified in a short-hairpin RNA screen for genes that retard
proliferation, i.e., genes that when knocked down permit
increased proliferation [11]. In our analysis, we used the
most stringent criterion among several presented in [11] to
select STOP genes: the genes for which at least four short-
hairpin RNAs increased cell proliferation by at least four-
fold. We determined the list of these genes on the basis of the
data in Table S7 in [11] (878 genes). For our analysis of
STOP genes, we used the Gene Set Enrichment Analysis
(GSEA) Preranked software tool [25] with the ‘‘classic
enrichment statistic,’’ i.e., the version of the enrichment
statistic that uses ranks without weights. GSEAPreranked
runs the analysis with a user-supplied ranked list of genes
and determines if a given set of genes shows statistically
significant enrichment at either end of the ranking. This is
done by computation of an enrichment score for the given
gene set that reflects how often members of the gene set
occur at the top or bottom of the ranked list.
Our analysis examined whether, compared with other
genes, STOP genes tended to have reduced copy number.
We ordered the genes in increasing order of their average
relative copy number across all samples, and then, to break
ties, in decreasing order of the correlation coefficient
between the genes’ average relative copy numbers and
expression levels. In the cases of the few remaining ties, we
used a random ordering. We tested this ordered list against
the STOP gene set. We obtained the relative copy number of
a gene in a sample by dividing the copy number of the gene in
the sample by the ASCAT-determined average ploidy of the
sample. We performed the analysis using several random
orderings, and we report the maximum p value over the
random orderings. Table S2 provides one such ordering.
Gene expression data
Gene expression data were obtained from Gene Expression
Omnibus (accession numbers GSE15459 and GSE34942).
We used COMBAT [26] as described in [27] to remove
batch effects.
Analysis of CYCLOPS genes
CYCLOPS genes are those for which ‘‘loss correlated with
a greater sensitivity to further gene suppression’’ [14]. For
our analysis we used the list of candidate genes in Table S2
in [14] and selected the genes with a false discovery rate of
less than 0.25, which was the criterion used in [14]. Fifty-
five genes satisfied this criterion; the main text of [14] is
apparently inconsistent in indicating 56 genes.
Results
We initially analyzed 113 gastric tumors with their paired
adjacent nonmalignant tissues using ASCAT (Table S3).
For 74 of the 113 pairs, ASCAT was able to estimate
allele-specific copy numbers across the genome. ASCAT
was unable to estimate allele-specific copy numbers for the
remaining pairs for the following reasons (Table S4): (1)
excessively variable LRR data that ASCAT was unable to
segment reasonably (12 tumors; Figs. S3a, S4, S5); (2)
BAFs that were flat, i.e., uniformly 0.5 (25 tumors;
Fig. S6a); or (3) apparently low tumor content as evi-
denced by very little variation in the segmented LRRs and
few divergences of the BAFs from 0.5 (two tumors). We
suspect that excessively variable LRRs are the result of
experimental artifacts, as shown in Figs. S3, S4, and S5.
We believe that very low proportions of malignant cells in
the tumor samples were responsible for the BAFs that were
uniformly 0.5, for the reasons described in the caption for
Fig. S6. Inspection of the 74 generated ASCAT profiles
revealed 12 profiles with large (more than 10 Mb)
homozygous deletions, which are likely incompatible with
cell survival. Therefore, these probably represent under-
estimates of average ploidies by ASCAT. Consequently,
we adjusted these profiles by selecting the next best solu-
tion found by ASCAT at a higher average ploidy.
bFig. 1 Example ASCAT profile and allele-specific copy numbers.
The data are from sample 980029. a log2 R ratio (LRR). Indices of
autosomal single-nucleotide polymorphisms (SNPs) that are heterozy-
gous in the nonmalignant sample are plotted along the x-axis. The y-
axis indicates LRRs of SNPs in the tumor relative to the nonmalignant
sample. Red dots show LRRs for each informative SNP, and green
dots show ASCAT’s segmentations. b B-allele frequency (BAF) for
the SNPs plotted in a. Red dots show BAFs for each SNP and green
dots show ASCAT’s segmentation. c The solution space for the two
parameters ‘‘ploidy’’ and ‘‘aberrant cell fraction,’’ with the location of
the chosen values marked by a cross. d ASCAT’s model of allele-
specific copy numbers. The y-axis indicates the estimated integer
chromosomal copy number. Red lines and green lines indicate the
higher-copy-number and lower-copy-number chromosomal haplo-
types, respectively. The lines are vertically offset slightly to avoid
superimposition. e The ASCAT aberration reliability score, a measure
of how well the model in d explains the segmented LRRs and BAFs.
Regions of copy-number loss according to our definition (total copy
number less than 0.7 times the average ploidy) can be found in d by
looking for segments that have total copy number (sum of the two
allele copy numbers given by the green line and the red line) less than
0.7 9 2.31 = 1.6. Chromosomes 10, 12, and 18 each contain a small
segment with total copy number 1 (red line at 1 and green line at 0,
indicated by arrows). The region of loss in chromosome 18 is very
small, and because of the plotting it is difficult to see the gap in the
red line. However the green line at copy number 0 is visible
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Landscape of copy-number loss and LOH in gastric
cancer
Genomic copy-number loss and LOH are pervasive in
gastric cancer (Figs. 2, S7, S8, Tables 1, S5). The pro-
portion of the genome subject to copy-number loss varies
considerably from tumor to tumor, with a median of 5.5 %,
and a mean of 12 % (range 0–58.5 %; Fig. S9a). In addi-
tion, an average of 22.1 % of each gastric cancer genome is
subject to LOH (range 0–77.7 %). Regions of copy-number
loss and LOH in individual tumors often encompass whole
chromosomes, chromosome arms, or regions of tens of
megabases (Figs. 2, 3, S7, S8 Table 1).
There are several large regions that are each subject to
copy-number loss in at least 20 % of tumors (Table 1).
One of these is a 46.7-Mb portion of 9p that contains nine
STOP genes, one CYCLOPS gene, and the TSG CDKN2A
(which encodes cyclin-dependent kinase inhibitor 2A)
(Fig. 3, panels a, b). This region also contains two other
genes, PTPRD and DOCK8, that have been proposed as
TSGs in other cancers [28–35]. An additional large region
of frequent copy-number loss affects much of the long arm
of chromosome 18 in approximately 20 % of tumors and
contains 13 STOP genes and two TSGs (Table 1, Fig. 3,
panels c, d). Finally, much of chromosome 4 undergoes
copy-number loss in many tumors, and contains 62 STOP
genes and three CYCLOPS genes (Table 1, Fig. S7).
STOP genes are enriched for copy-number loss
We analyzed the prevalence of deleted STOP genes in the
74 tumors and found that, on average, 91.11 STOP genes
are subject to copy-number loss per tumor (median 35,
range 0–452; Table S6, Fig. S9b). To test if, compared
with other genes, STOP genes tend to have lower copy
number in tumors, we performed a GSEAPreranked test
[25] using the STOP genes as the gene set. The reasoning
behind this hypothesis is that STOP genes, when reduced in
copy number, would have lower expression and therefore
would tend to inhibit proliferation less. Therefore, we
restricted our attention to genes with significant positive
correlations between average relative copy numbers and
messenger RNA (mRNA) expression level. We ranked
these genes on the basis of their average copy numbers
relative to their tumor’s average ploidy across the 74
tumors, and then, to break ties, on the basis of the Spear-
man correlation coefficient between average relative copy
number and expression. In this analysis, the STOP genes
indeed tended to have reduced copy number (GSEA
p\ 0.02; Fig. 4). As a sanity check, we also performed an
analysis based on resampling. For this, instead of using the
STOP gene set (which consists of 878 genes), we randomly
selected 878 genes from the genome and ranT
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GSEAPreranked with the list of ranked genes described
above. We repeated this 1000 times and then determined
how many times the normalized enrichment score was
higher than the one obtained when we used the STOP gene
set. In our analysis this happened four times out of 1000.
Therefore, the empirical p value is 0.004, indicating that
STOP genes indeed have reduced copy number compared
with the other genes in the genome.
CYCLOPS genes are affected by copy-number loss
in many tumors
CYCLOPS genes are an additional class of genes of
interest in regions of copy-number loss; these are genes for
which copy-number loss indicates a potential vulnerability
to therapeutic inhibition [14]. Unlike the copy-number loss
of a STOP gene, which is thought to promote proliferation,
the copy-number loss of a CYCLOPS gene is thought to
confer no advantage to the cancer cell, but rather to acci-
dentally make the cancer more sensitive to inhibition of
that gene. We found that from the total of 55 CYCLOPS
genes, on average, 6.81 CYCLOPS genes were subject to
copy-number loss in each tumor (median 2, range 0–39;
Table S7, Fig. S9c). Forty-seven tumors had at least one
CYCLOPS gene subject to copy-number loss, and 51 of the
55 CYCLOPS genes underwent copy-number loss in at
least one gastric adenocarcinoma (Table S8). However, for
only nine of these was the copy-number loss associated
with lower mRNA levels (Table S8). On average, 1.6 of
these nine genes were subject to copy-number loss per
tumor (median 1, range 0–9), and 38 tumors (51.4 %) had
at least one of these nine CYCLOPS genes with reduced
copy number. The genes that were both subject to copy-
number loss in at least 10 % of the tumors and also sub-
stantially downregulated when deleted (Table S8) are
EEF2 (which encodes eukaryotic translation elongation
factor 2), ETFDH (which encodes electron-transferring-
flavoprotein dehydrogenase), and ENC1 (which encodes
ectodermal-neural cortex 1). Visual examination of the
LRRs and BAFs of these genes in several tumors strongly
supports the copy-number loss assessed by ASCAT
(Fig. S10).
Correlation of copy-number loss patterns
with clinical characteristics
We explored whether there were any significant correla-
tions between the detected copy-number loss patterns and
the clinical information associated with our samples. In
multivariate survival analysis (Cox proportional hazards
models) we found several frequent regions of copy-number
loss (17p, 3p, and 5q) that were correlated with survival
(Table S9). However, analysis of 212 gastric tumors from
The Cancer Genome Atlas (http://cancergenome.nih.gov/)
did not show a significant association between copy-num-
ber loss of these regions and survival. Possibly the biology
of the tumors was different between the two patient pop-
ulations, or possibly this was a chance result in our data.
We also examined associations between copy-number-
loss in the regions shown in Table 1 and several other
covariates. These covariates were gender, tumor stage,
tumor grade, Lauren classification, and adjuvant treatment.
None were significant in univariate analysis after correc-
tion for multiple hypothesis testing (Table S10). With
respect to lack of association of any particular copy-num-
ber alteration with the Lauren classification, previous
studies also did not detect systematic differences in copy-
number alterations between the Lauren subtypes [36, 37].
Fig. 2 Genome-wide overview
of frequencies of copy-number
loss and loss of heterozygosity
across 74 gastric tumors. Copy-
number loss is defined as a
region where the genomic copy
number is less than 0.7 times
the average ploidy. See Figs. S7
and S8 for detailed plots across
each chromosome
cFig. 3 Regions of copy-number loss across chromosomes 9 and 18.
a The proportion of tumors showing copy-number loss at each single-
nucleotide polymorphism on chromosome 9, based on ASCAT’s
allele-specific copy-number analysis. The locations of Copy-number
alterations Yielding Cancer Liabilities Owing to Partial losS
(CYCLOPS) genes (red) and well-established tumor suppressor
genes (black) are indicated. b Regions of copy-number loss in
specific tumors. c, d Analogous information for chromosome 18.
Copy-number loss is defined as a region where the genomic copy
number is less than 0.7 times the average ploidy. cen centromere
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We also examined association of copy-number alterations
with the genomic intestinal (G-INT)/genomic diffuse (G-
DIF) classification [38], and again observed no significant
association after correction for multiple hypothesis testing.
The G-INT/G-DIF classification is a gene-expression
(mRNA)-based classification that was developed on gastric
cancer cell lines and then applied to primary gastric cancer
tumors. By way of background, we note that, although the
G-INT subtype is enriched for Lauren intestinal-subtype
tumors and the G-DIF subtype is enriched for Lauren dif-
fuse-subtype tumors, the association is not absolute. There
are diffuse-subtype tumors in the G-INT subtype and
intestinal-subtype tumors in the G-DIF subtype.
Discussion
Limitations
Genome-wide analyses of copy-number loss and LOH are
challenging owing to the mixture of malignant and non-
malignant cells in tumor samples. No standard analytical
approach has emerged as the most appropriate in tumors
with low proportions of malignant cells. As noted earlier,
we evaluated ASCAT on a dilution series of mixed
malignant and nonmalignant DNA [20, 21]. ASCAT per-
formed well, even when analyzing tumors with low pro-
portions of malignant cells. Nevertheless, in the current
study, ASCAT was unable to analyze 39 tumors. Among
these, 25 had flat BAFs. For these we believe the main
issue was a very low proportion of malignant cells, for the
reasons described in the caption for Fig. S6. Supporting
this view, examination of the BAFs of 34 gastric cancer
cell lines in the Cancer Cell Line Encyclopedia [39]
revealed none with completely flat BAFs, suggesting that
most gastric adenocarcinomas have at least some regions of
allelic imbalance. We also note that our estimates of the
proportions of tumors with LOH at each chromosome arm
are statistically indistinguishable from previous estimates
based on microsatellite assays (Table S11) [7], suggesting
that the current analysis is correct. In addition to the 25
tumors with flat BAFs, ASCAT was unable to complete
analysis of 12 tumors for which the LRRs were excessively
variable. As described in Figs. S3, S4, and S5, we believe
these were due to experimental artifacts.
Candidate TSGs subject to frequent copy-number
loss
We found that much of the short arm of chromosome 9 is a
hot spot for copy-number loss and LOH in gastric cancer
(Table 1, Figs. 3 panels a, b, S7, S8). The TSG CDKN2A
is located in this region and is mutated in numerous tumor
types [40–42]. This gene is frequently deleted or hyper-
methylated in gastric cancer [43–46]. However, it is nev-
ertheless possible that this region contains other TSGs that
contribute to gastric carcinogenesis. Two genes that are
promising in this regard are PTPRD (which encodes pro-
tein tyrosine phosphatase, receptor type, D) and DOCK8
(which encodes dedicator of cytokinesis 8). PTPRD is
inactivated by gene deletion or mutation in various cancers
[28–33], and was previously noted to undergo LOH in
gastric cancer [47]. A recent study also showed homozy-
gous deletion of this gene in gastric cancer cell lines [48].
In our study, PTPRD was subject to LOH in 36 of 74
tumors and subject to copy-number loss in 25 tumors.
DOCK8 is a guanine nucleotide exchange factor that acti-
vates Rho GTPases. Homozygous deletion and reduced
expression of DOCK8 were observed in lung cancer [34,
35]. In this study, DOCK8 was subject to LOH in 37
tumors and had reduced copy number in 26 tumors. Thus,
PTPRD and DOCK8 deserve more scrutiny as potential
TSGs in gastric adenocarcinoma.
Comparison with copy-number loss patterns
in other cancer types
The regions most frequently subject to copy-number loss in
the gastric adenocarcinomas we studied are 3p, 4, 9p, 17p,
and 18q. Several other cancer types also have frequent
losses in all of these regions [49]. These types include non-
small-cell lung carcinoma, pancreatic adenocarcinoma,
renal cell carcinoma, and esophageal carcinoma. In
Fig. 4 Gene Set Enrichment Analysis shows that suppressor of
tumorigenesis and/or proliferation (STOP) genes tend to have lower
average relative copy number. As discussed in the text, we restricted
our attention to genes for which at least four short-hairpin RNAs
increased cell proliferation by at least fourfold. a Running enrichment
score for the STOP gene set against the list of genes ranked by their
average relative copy number across all 74 samples, and then, to
break ties, by the correlation coefficient between their average
relative copy number and messenger RNA expression level. b Vertical
black lines indicate the locations of STOP genes in the ranked list of
genes
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addition, losses of 3p and 9p are shared with head and neck
cancers, malignant melanocytic neoplasia, and small cell
lung and squamous cell carcinomas. Losses of 4, 17p, and
18q are also found frequently in ovarian, hepatocellular,
cervical, and bladder cancers [49]. This suggests that some
of the STOP gene contribution to tumorigenesis is shared
across cancers. It also suggests that therapies based on
CYCLOPS genes might be applicable to multiple cancer
types.
Implications of STOP genes subject to copy-number
loss
We found that a substantial number of antiproliferative
STOP genes were subject to copy-number loss in each
tumor, and GSEAPreranked showed that STOP genes tend
to have a lower copy-number compared with the other
genes. The initial study of STOP genes [11] analyzed their
relationship to the recurrent deletions that were originally
reported in [13]. Although a large number (3131) of can-
cers were studied, these included only 23 gastric cancers
(Supplementary Table 1 in [13]). This previous study [11]
also concluded that GO genes–genes whose depletion
limits proliferation—were impoverished in regions of
recurrent copy-number loss. We also examined this ques-
tion, but found no evidence that GO genes are impover-
ished in lower copy-number regions in gastric
adenocarcinoma (Fig. S11).
Implications of CYCLOPS genes subject to copy-
number loss
We found that 51 of the candidate CYCLOPS genes
identified in [14] were subject to copy-number loss in at
least one gastric adenocarcinoma. However, for only nine
of these genes was the copy-number loss in fact associated
with reduced mRNA levels (Table S8), suggesting that
only 16 % of the candidate CYCLOPS genes actually
constitute potential therapeutic opportunities in gastric
cancer. Indeed, Nijhawan et al. [14] did not examine the
extent to which the candidate CYCLOPS genes were in
fact downregulated when deleted. Thus, the therapeutic
opportunities presented by CYCLOPS genes may be more
limited than they would seem on the basis of deletions of
the full set of CYCLOPS genes. Nevertheless, 38 of the
tumors in the current study showed copy-number loss of at
least one of the nine CYCLOPS genes for which reduced
copy number was associated with reduced expression
(Table S8).
Comparison of the findings of the current study with
those of the previous study of CYCLOPS genes [14] sug-
gests considerable heterogeneity in the patterns of
CYCLOPS gene loss across cancer types. In the gastric
tumors we studied, on average, each CYCLOPS gene was
subject to copy-number loss in 12.4 % of tumors (range
0–29.7 %), which was lower than the average of 18 %
(range 8–33 %) reported for 3131 tumors in [14]. These
differences are reflected on a gene-by-gene basis. We take
as an example the SNRPB gene (which encodes small
nuclear ribonucleoprotein polypeptides B and B1), which
was a high-ranking CYCLOPS candidate that was studied
experimentally in [14]. This gene was subject to copy-
number loss in 13 % of the 3131 cancers studied in [14],
but had reduced copy number only once among the 74
gastric tumors we studied, a significantly lower proportion
(p = 0.001, Fisher’s exact test). Indeed, many top-ranked
CYCLOPS genes in [14] were significantly less often
deleted in the gastric adenocarcinomas than in the 3131
tumors studied previously (Table S12).
Summary
This analysis of copy-number loss in gastric adenocarci-
nomas showed that STOP genes tend to have a lower copy
number compared with other genes, suggesting that the
copy-number loss of these genes may contribute to gastric
carcinogenesis. In addition, the presence of deleted and
downregulated CYCLOPS genes in 51 % of the tumors
suggests potential therapeutic targets in these tumors.
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